Skip to content
value.today

Lyell Immunopharma, Inc.: insider trading

92 trades by 21 directors, officers and 10% owners since 2021, from their SEC Form 4 and 5 filings.

Bought, 12 months
$37.5 M
4 purchases by 4 insiders
Sold, 12 months
$613 K
29 sales by 7 insiders
Bought, 3 months
$25.0 M
2 purchases
Sold, 3 months
$216 K
9 sales

Insider buying and selling by month

Open-market purchases and sales by value, last three years.

$25.0 M-$264 K$0Mar 2025: bought $450 K (5 trades), sold $0 (0 trades)Mar 25Aug 2025: bought $0 (0 trades), sold $115 K (12 trades)Nov 2025: bought $0 (0 trades), sold $14 K (4 trades)NovDec 2025: bought $0 (0 trades), sold $74 K (2 trades)Feb 2026: bought $0 (0 trades), sold $264 K (7 trades)FebMar 2026: bought $12.5 M (2 trades), sold $0 (0 trades)May 2026: bought $0 (0 trades), sold $16 K (4 trades)MayJun 2026: bought $0 (0 trades), sold $25 K (1 trades)Jul 2026: bought $0 (0 trades), sold $274 (2 trades)JulAug 2026: bought $0 (0 trades), sold $205 K (7 trades)Sep 2026: bought $0 (0 trades), sold $6 K (1 trades)SepOct 2026: bought $0 (0 trades), sold $4 K (1 trades)Nov 2026: bought $25.0 M (2 trades), sold $19 K (4 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals

Insiders (21)

Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.

Lyell Immunopharma, Inc. insiders
InsiderShares owned directlyBought, 12 mSold, 12 mLatest trade
Gary K. LeeChief Scientific Officer16,091—$72 K
Lynn SeelyPresident and CEO, Director63,354—$355 K
Stephen J. HillChief Operating Officer16,728—$51 K
Veronica Sanchez BulisVP, Corporate Controller14,383—$100 K
ARCH Venture Fund XIII, L.P.10% owner—$25.0 M—
ARCH Venture Partners IX, LLC10% owner———
Jarrad Mattieu AguirreChief Medical Officer19,857—$4 K
David ShookChief Medical Officer20,423—$31 K
Innovative Cellular Therapeutics Holdings Ltd10% owner2.82 M—$274
ARCH Venture Partners IX Overage, L.P.10% owner———
Paul L. Berns10% owner—$12.5 M—
Charles W. NewtonChief Financial Officer15,306——
Otis W. BrawleyDirector35,640——
Sumant RamachandraDirector———
Richard KlausnerDirector———
Matthew LangChief Business Officer162,500——
Hans Edgar BishopDirector4.69 M——
Cathy FriedmanDirector———
ARCH Venture Fund IX, L.P.10% owner———
Glaxosmithkline PLC10% owner———
Robert NelsenDirector, 10% owner———

Trades#

Lyell Immunopharma, Inc.: insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Lynn SeelyPresident and CEO, DirectorSell-545$15.93$9 K63,354Form 4
filed Stephen J. HillChief Operating OfficerSell-88$15.93$1 K16,728Form 4
filed Gary K. LeeChief Scientific OfficerSell-129$15.93$2 K16,091Form 4
filed Veronica Sanchez BulisVP, Corporate ControllerSell-416$15.93$7 K14,383Form 4
filed ARCH Venture Fund XIII, L.P.10% ownerBuyindirect+2.32 M$10.77$25.0 M3.75 MForm 4
filed ARCH Venture Partners IX, LLC10% ownerBuyindirect+2.32 M$10.77—3.75 MForm 4
filed Jarrad Mattieu AguirreChief Medical OfficerSell-422$8.630$4 K19,857Form 4
filed David ShookChief Medical OfficerSell-500$12.70$6 K20,423Form 4
filed Lynn SeelyPresident and CEO, DirectorSell-9,589$15.54$149 K63,899Form 4
filed Stephen J. HillChief Operating OfficerSell-989$15.54$15 K16,816Form 4
filed Gary K. LeeChief Scientific OfficerSell-1,457$15.54$23 K16,220Form 4
filed Stephen J. HillChief Operating OfficerSell-89$14.34$1 K17,805Form 4
filed Lynn SeelyPresident and CEO, DirectorSell-390$14.34$6 K73,488Form 4
filed Veronica Sanchez BulisVP, Corporate ControllerSell-621$14.34$9 K14,799Form 4
filed Gary K. LeeChief Scientific OfficerSell-131$14.34$2 K17,677Form 4
filed Innovative Cellular Therapeutics Holdings Ltd10% ownerOther-38,500——2.82 MForm 4
filed Innovative Cellular Therapeutics Holdings Ltd10% ownerOther-44,000——2.77 MForm 4
filed Innovative Cellular Therapeutics Holdings Ltd10% ownerSell10b5-1 plan-10$13.70$1372.86 MForm 4
filed Innovative Cellular Therapeutics Holdings Ltd10% ownerSell10b5-1 plan-10$13.73$1372.86 MForm 4
filed Innovative Cellular Therapeutics Holdings Ltd10% ownerOther-76,000——2.86 MForm 4
filed Innovative Cellular Therapeutics Holdings Ltd10% ownerOther-66,500——2.93 MForm 4
filed David ShookChief Medical OfficerSell-1,977$12.64$25 K20,923Form 4
filed Veronica Sanchez BulisVP, Corporate ControllerSell-217$18.91$4 K15,420Form 4
filed Stephen J. HillChief Operating OfficerSell-89$18.92$2 K17,894Form 4
filed Gary K. LeeChief Scientific OfficerSell-130$18.92$2 K17,808Form 4
filed Lynn SeelyPresident and CEO, DirectorSell-388$18.91$7 K73,878Form 4
filed ARCH Venture Partners IX Overage, L.P.10% ownerBuyindirect+488,090$25.61—1.43 MForm 4
filed Paul L. Berns10% ownerBuyindirect+488,090$25.61$12.5 M1.43 MForm 4
filed Lynn SeelyPresident and CEO, DirectorSell-7,455$23.39$174 K74,266Form 4
filed Gary K. LeeChief Scientific OfficerSell-1,671$23.39$39 K16,938Form 4
filed Stephen J. HillChief Operating OfficerSell-1,236$23.39$29 K17,795Form 4
filed Veronica Sanchez BulisVP, Corporate ControllerGrant or award+8,750——15,891Form 4
filed Veronica Sanchez BulisVP, Corporate ControllerSell-254$23.12$6 K15,637Form 4
filed Stephen J. HillChief Operating OfficerSell-109$23.12$3 K19,031Form 4
filed Lynn SeelyPresident and CEO, DirectorSell-438$23.12$10 K81,721Form 4
filed Gary K. LeeChief Scientific OfficerSell-147$23.12$3 K18,609Form 4
filed Stephen J. HillChief Operating OfficerGrant or award+4,000——19,140Form 4
filed Lynn SeelyPresident and CEO, DirectorGrant or award+20,000——82,159Form 4
filed Gary K. LeeChief Scientific OfficerGrant or award+4,000——18,756Form 4
filed Veronica Sanchez BulisVP, Corporate ControllerSell-936$32.32$30 K7,141Form 4
filed Veronica Sanchez BulisVP, Corporate ControllerSell-1,136$38.67$44 K8,077Form 4
filed Veronica Sanchez BulisVP, Corporate ControllerSell-239$16.10$4 K9,213Form 4
filed Lynn SeelyPresident and CEO, DirectorSell-412$16.11$7 K67,159Form 4
filed Gary K. LeeChief Scientific OfficerSell-138$16.16$2 K15,366Form 4
filed Stephen J. HillChief Operating OfficerSell-95$16.12$2 K15,750Form 4
filed Stephen J. HillChief Operating OfficerSell-1,004$10.54$11 K15,845Form 4
filed Gary K. LeeChief Scientific OfficerSell-1,453$10.54$15 K15,504Form 4
filed Lynn SeelyPresident and CEO, DirectorSell-7,257$10.54$76 K67,571Form 4
filed Charles W. NewtonChief Financial OfficerSell-1,453$10.54—15,306Form 4
filed Stephen J. HillChief Operating OfficerGrant or award+8,000——16,849Form 4
filed Gary K. LeeChief Scientific OfficerGrant or award+8,000——16,957Form 4
filed Lynn SeelyPresident and CEO, DirectorGrant or award+40,000——74,828Form 4
filed Charles W. NewtonChief Financial OfficerGrant or award+8,000——16,759Form 4
filed Lynn SeelyPresident and CEO, DirectorSell-406$10.34$4 K34,828Form 4
filed Charles W. NewtonChief Financial OfficerSell-136$10.34$1 K8,759Form 4
filed Stephen J. HillChief Operating OfficerSell-94$10.34$9728,849Form 4
filed Gary K. LeeChief Scientific OfficerSell-136$10.34—8,957Form 4
filed Gary K. LeeChief Scientific OfficerSell-131$10.53—9,093Form 4
filed Lynn SeelyPresident and CEO, DirectorSell-391$10.53$4 K35,234Form 4
filed Charles W. NewtonChief Financial OfficerSell-131$10.53$1 K8,895Form 4
filed Stephen J. HillChief Operating OfficerSell-91$10.53$9588,943Form 4
filed David ShookChief Medical OfficerGrant or award+21,900——21,900Form 4
filed Otis W. BrawleyDirectorBuy+35,640$0.560$20 K35,640Form 4
filed Sumant RamachandraDirectorBuyindirect+200,000$0.580$116 K200,000Form 4
filed Charles W. NewtonChief Financial OfficerBuyindirect+200,000$0.560$112 K200,000Form 4
filed Richard KlausnerDirectorBuyindirect+158,000$0.600$95 K843,365Form 4
filed Lynn SeelyPresident and CEO, DirectorBuy+175,000$0.610$107 K712,500Form 4
filed Gary K. LeeChief Scientific OfficerGrant or award+112,500——176,696Form 4
filed Charles W. NewtonChief Financial OfficerGrant or award+112,500——172,725Form 4
filed Matthew LangChief Business OfficerGrant or award+112,500——162,500Form 4
filed Lynn SeelyPresident and CEO, DirectorGrant or award+337,500——537,500Form 4
filed Stephen J. HillChief Operating OfficerGrant or award+112,500——172,899Form 4
filed Matthew LangChief Business OfficerGrant or award+50,000——50,000Form 4
filed Stephen J. HillChief Operating OfficerGrant or award+40,000——48,928Form 4
filed Gary K. LeeChief Scientific OfficerGrant or award+40,000——52,700Form 4
filed Charles W. NewtonChief Financial OfficerGrant or award+40,000——48,729Form 4
filed Lynn SeelyPresident and CEO, DirectorGrant or award+200,000——200,000Form 4
filed Richard KlausnerDirectorSellindirect-58,020$2.280$132 K930,880Form 4
filed Richard KlausnerDirectorSellindirect-11,100$6.400$71 K988,900Form 4
filed Hans Edgar BishopDirectorOption exercise+145,380$0.100$15 K4.69 MForm 4
filed Hans Edgar BishopDirectorOption exercise+993,428$0.100$99 K4.54 MForm 4
filed Cathy FriedmanDirectorOtherindirect-3.77 M——0Form 4
filed Cathy FriedmanDirectorOtherindirect+218,722——236,370Form 4
filed Hans Edgar BishopDirectorConversion+546,806——3.55 MForm 4
filed ARCH Venture Fund IX, L.P.10% ownerConversionindirect+18.21 M——18.21 MForm 4
filed Glaxosmithkline PLC10% ownerConversionindirect+30.25 M——30.25 MForm 4
filed Cathy FriedmanDirectorConversionindirect+3.77 M——3.77 MForm 4
filed Richard KlausnerExecutive Chairman, DirectorConversionindirect+3.77 M——3.77 MForm 4
filed Robert NelsenDirector, 10% ownerConversionindirect+18.21 M——18.21 MForm 4
filed ARCH Venture Fund IX, L.P.10% ownerConversionindirect+18.21 M——18.21 MForm 4
filed Cathy FriedmanDirectorBuyindirect+17,648$17.00$300 K17,648Form 4
filed Robert NelsenDirector, 10% ownerConversionindirect+18.21 M——18.21 MForm 4

Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice